NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NADH powder
3、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
4、Provide one-stop product solution customization service
Improved energy levels
Not only does NADH act as an important coenzyme in aerobic respiration, the [H] of NADH also carries a large amount of energy. Studies have demonstrated that extracellular use of NADH promotes increased intracellular ATP levels, suggesting that NADH penetrates cell membranes and elevates intracellular energy levels. On a macro level, exogenous supplementation of NADH helps to restore energy and enhance appetite. The increase in energy levels in the brain also helps to improve mental performance and sleep quality. NADH has been used overseas to improve chronic fatigue syndrome, increase exercise endurance, jet lag and other areas.
Cellular protection
NADH is a strong antioxidant that naturally occurs in cells and reacts with free radicals to inhibit lipid peroxidation, protecting mitochondrial membranes and mitochondrial function. It has been found that NADH can reduce oxidative stress in cells caused by various factors such as radiation, drugs, toxic substances, strenuous exercise and ischemia, thus protecting vascular endothelial cells, hepatocytes, cardiomyocytes, fibroblasts and neurons. Therefore, injectable or oral NADH is used clinically to improve cardiovascular and cerebrovascular diseases, and as an adjunct to cancer radiotherapy. Topical NADH has been shown to be effective in the treatment of rosacea and contact dermatitis.
Promotion of neurotransmitter production
Studies have shown that NADH significantly promotes the production of the neurotransmitter dopamine, a chemical signal that is essential for short-term memory, involuntary movements, muscle tone and spontaneous physical responses. It also mediates the release of growth hormone and determines muscle movement. Without sufficient dopamine, muscles become stiff. Parkinson's disease, for example, is caused in part by a disruption of dopamine synthesis in brain cells. Preliminary clinical data suggest that NADH can help improve the symptoms of Parkinson's disease [9]. NADH also promotes the biosynthesis of norepinephrine and serotonin, showing good potential for use in the relief of depression and Alzheimer's disease.
The main methods of NADH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme become the mainstream method owing to the advantages of pollution free, high level of purity and stability.
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes
First, inspect the factory. After some screening, NADH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NADH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NADH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
1. Introduction According to the 2020 report of World Health Organization (WHO), there are approximately 2.3 million cases with breast cancer worldwide. Breast cancer has emerged as one of the most malignant tumor in females with significant incidence rate. Although great progress has made in improving the cure rate of early-stage breast cancer in recent years, advanced breast cancer is still hard to be cured. How to reduce the risk of recurrence and metastasis of early-stage breast cancer as well as prolong the survival of patients with advanced breast cancer is still a challenge in the clinical treatment of breast cancer. Notably, ginsenoside Rh2 (GRh2) exerts prominent impacts on retarding the progression of breast cancer via strengthening the immune surveillance of natural killer (NK) cells, a kind of cytotoxic innate lymphocytes critical for tumor immune response. 2. The repressive role of GRh2 in the progression of breast cancer GRh2 hinders the growth, proliferation and metastasis of breast cancer. Simply put, the body weight and tumor volume of model mice are markedly reduced post treatment of GRh2 (10 mg/kg and 20 mg/kg). In addition, the proliferating rate of breast cancer cells is repressed by GRh2 in a dose-dependent manner (5, 10 and 20 mg/kg). Upon the treatment of GRh2 (20 mg/kg), the loss of lung capacity is obviously reduced and the lung metastases formed by MDA-MB-231 tumor cells are strikingly mitigated as well, with no apparent liver metastatic nodules. 3. The enhanced killing effect of NK cells on breast cancer cells following GRh2 treatment GRh2 exerts remarkable effects on retarding the progression of breast cancer via improving the killing ability of NK92MI cells. In a nutshell, the mRNA expression levels of killing mediators perforin and IFN-γ in NK92MI cell-breast cancer cell co-culture system are explicitly upregulated post GRh2 treatment. Strikingly, the reduced lung metastasis of breast cancer by GRh2 is almost counteracted upon the depletion of NK cells. Relative to that of the vehicle control, the amount of CD107a, a degranulation marker of NK cells, is overtly elevated in the presence of GRh2 (20 mg/kg), verifying the enhanced killing activity of NK cells on breast cancer. 4. The underlying molecular mechanism of GRh2 on potentiating the NK cell activity against breast cancer Breast cancer cells reduce the recognition by NKG2D through proteolytic shedding MICA mediated by ERp5 to escape NK cell surveillance. GRh2 interferes with the formation of soluble MICA (sMICA) by suppressing the expression of ERp5 to increase the contents of killing mediators from NK cells, thereby exerting striking effects on fighting against breast cancer. 5. Conclusion GRh2 potentiates the cytotoxic effect of NK cells and enhances the immune surveillance function of NK cells to fight against breast cancer, which may be a potent drug candidate for the prevention and treatment of breast cancer. Reference [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 [2] Yang C, Qian C, Zheng W, et al. Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer. Phytomedicine. 2024;123:155180. doi:10.1016/j.phymed.2023.155180 Product advantages of BONTAC ginsenoside Rh2 BONTAC is the first enterprise worldwide that can provide national mass production of ginsenosides (Rh2) by enzymatic synthesis, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.
Introduction On March 28, 2024, Digital Health and Precise Nutrition Forum & Annual Conference of Health Industry in 2023 is held in Shenzhen, China. By virtue of the technical innovation in synthetic biology, far-reaching industry impact and positive commitment to social responsibility, BONTAC has been awarded 4 more honors in the heath industry, namely the "The Benchmarking Enterprise of Shenzhen Health Industry in 2023", "The Most Valuable Investment Enterprise of Shenzhen Health Industry in 2023", "Special Contribution Award for Shenzhen Health Industry in 2023" and "The Excellent Case in Shenzhen Health Industry Development Report (2022)". About Digital Health and Precise Nutrition Forum & Annual Conference of Health Industry in 2023 This conference is organized by Shenzhen Health Industry Alliance, Shenzhen Association for the Development & Promotion of Health Industry and Shenzhen Health Care Association, aiming to award and recognize the paragons in the health industry who make great contributions with their practical actions. They represent the top level and mainstream of Shenzhen in health industry. Evaluation criteria for two of the awards As for “The Most Valuable Investment Enterprise of Shenzhen Health Industry in 2023", one should be equipped with: * Market share, brand impact and technical innovation ability * Explicit goal, customer demand and operation means * Leading technology, products or services * Management team with abundant experience and professional ability For the Benchmarking Enterprise of Shenzhen Health Industry in 2023, the selected enterprises should have: * Certain industry impacts * Achievement in scientific innovation, intellectual property, etc. * Active participation in the drafting of international/national/industry standard * An efficient and professional team * Positive commitment to the social responsibility Professor Zhang’s speech in round-table dialogue Professor Zhang, the chief scientist and founder in BONTAC, has been invited to participate in the round-table dialogue themed by “Digitization Empowers Nutrition and Health”. She shares profound and unique insights upon the research and practice of coenzyme raw materials in the field of precise nutrition. “BONTAC realizes the efficient synthesis and precise application of coenzyme raw materials in the fields such as food, agriculture and animal nutrition through deep integration of big data with AI technology”, Professor Zhang said. “We not only focus on the extensive use of coenzyme raw materials, but also emphasize their safety and function, with the purpose of satisfying everyone's demand on precise nutrition as well as promoting the continuous innovation and development of the health industry. Novel trend towards health industry Under the guidance of “Health China” strategy, there is an increasing trend towards to the deep integration of digital industry with health industry in current society. The reform of digital technology opens up unprecedented opportunities for the health industry, driving the intelligence, precision and personalization of health. In Shenzhen, a new blueprint for the high-quality development of “20+8” industry clusters (top 20 strategic emerging industrial clusters and 8 industries of the future) has been plotted in 2023. With the continuous optimization of industry structure, the health industry in Shenzhen has been developed rapidly, which infuses new energy for the economy and provides solid support for the citizen’s health and well-being. BONTAC as a driver of health and well-being BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, who adheres to adopt the innovation-driven scientific strategy, with more than 170 invention patents, making great contributions to the health industry. Strikingly, a independent platform for directed evolution has been established in BONTAC, where premium enzyme species can be screened by AI to provide strong support for the production of high-quality coenzyme raw materials, driving the integration of digital industry with health industry. In 2024, BONTAC will continue to stick to our mission of “Green Bio-Tech, Healthier and Better Life!” and actively respond to the appeal in “Outline of the Program for Health China 2030”, promoting the deep integration of synthetic biology with health industry and constructing a better health service system.
Introduction Glaucoma is regarded as the second dominant cause of blindness across the world. With the amounting number and proportion of elderly people, it is estimated that 111.8 million people will have glaucoma by 2040. Nicotinamide riboside (NR) has been attested to protect retinal ganglion cells from the stress of elevated intraocular pressure and optic nerve crush. Glaucoma patients can protect their optic nerves by oral administration of NR at a dose of 300 mg (approximately 1.18 mM). The abovementioned protective effects of NR may be achieved by its antioxidant and antifibrotic properties. About glaucoma Glaucoma is a typical ocular disease characterized by atrophy and depression of the optic nerve head, visual field defects, and diminution of vision. The pathologically increased intraocular pressure and insufficient blood supply to the optic nerve are deemed as the primary risk factors for the development of the disease. In addition to those with family history of glaucoma, people with severe myopia/hyperopia, hypertension, hyperlipidemia, hyperglycemia and long-term use of corticosteroid medications, especially eye drops, are at high risk for glaucoma. Extraordinary role of NR in protecting HTMs against oxidative stress In glaucoma, oxidative stress can trigger TM degeneration, thereby resulting in intraocular hypertension. Herein, an oxidative damage model is established in vitro by incubation of human trabecular meshwork (HTM) cells with 200 μM H2O2 for 24 h. As expected, NR hampers H2O2-induced apoptosis in HTM cells, as evidenced by the upregulation of the anti-apoptotic protein Bcl-2 and downregulation of apoptotic protein Bax. Conversely, NR boosts the viability of oxidative-damaged HTM cells. In addition, NR can shield HTM cells from oxidative stress by lowering ROS and superoxide anion levels. Apart from this, NR overtly improves the H2O2-induced decrease in the mitochondrial membrane potential (MMP) in HTM cells, hinting its antioxidant effect possibly achieved by maintaining mitochondrial homeostasis. Underlying mechanism regarding the antioxidant role of NR in HTM cells MAPK and JAK2/Stat3 pathways are related to NR-alleviated HTM cell apoptosis during oxidative stress. In the MAPK pathway, H2O2 leads to the downregulation of p-P38/P38 ratio and upregulation of p-ERK1/2 protein expression, which are offset by intervention with NR. In the JAK2/Stat3 pathway, H2O2 induces downregulation of p-JAK2 protein expression, while NR runs oppositely. Potential antifibrotic role of NR in HTM cells Considering that transforming growth factor-beta 2 (TGF-β2), a profibrotic cytokine, is also a major contributor to glaucomatous HTM dysfunction, an HTM cell model of fibrosis is constructed by induction of TGF-β2 at 10 ng/mL for 48 h. Remarkably, NR prevents TGF-β2-induced fibrosis by reducing extracellular matrix (ECM) deposition in HTM cells. Concretely, the mRNA and protein levels of fibronectin (FN) are elevated in the TGF-β2-treated HTM cells, which however are counteracted by NR. Conclusion NR can boost the viability, proliferation and MMP oxidative damage in H2O2-induced HTM cells, and hamper TGF-β2-induced fibrosis, which is linked to the MAPK and JAK2/Stat3 pathways. NR may be a potential therapeutic agent for glaucoma by inhibiting oxidative damage and fibrosis in HTM cells. Reference Zeng Y, Lin Y, Yang J, et al. The Role and Mechanism of Nicotinamide Riboside in Oxidative Damage and a Fibrosis Model of Trabecular Meshwork Cells. Transl Vis Sci Technol. 2024;13(3):24. doi:10.1167/tvst.13.3.24 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 173 BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, or costs resulting or arising directly or indirectly from your reliance on the information and material on this website.